Press Release - HBM Holdings

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release

Press Release In the News Image Library Awards & Recognitions

January 28, 2021

Harbour BioMed’s Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis

Cambridge, MA, Rotterdam, NL, Suzhou, CN— January 28, 2021. Harbour BioMed (HBM) (HKEX: 02142.HK) announced today that China Center for...
View more
December 17, 2020

Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange

CAMBRIDGE, Mass., SUZHOU, China, December 17, 2020 – HBM Holdings Limited (“Harbour BioMed”, “HBM” or the "Company”; S...
View more
December 15, 2020

Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials

CAMBRIDGE, Mass., SUZHOU, China, UTRECHT, The Netherlands, December 14, 2020 – Harbour BioMed (HBM)(HKEX:02142) and Utrecht University (UU) today announc...
View more
December 09, 2020

HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering

This press release is NOT for release, publication, distribution, directly or indirectly, in or into the United States (including its terri...
View more
November 16, 2020

Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society

The proof-of-concept study demonstrated efficacy, safety, and tolerability of Tanfanercept for the treatment of moderate-to-severe dry eye disease (DED) in Chi...
View more
September 30, 2020

Harbour BioMed Announces Dosing of First Patient in Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia

Cambridge, MA, Rotterdam, NL, Suzhou, CN— September 30, 2020. Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today ...
View more
September 21, 2020

Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors

Cambridge, MA, Rotterdam, NL, Suzhou, CN – September 21, 2020. Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company ...
View more
September 11, 2020

Harbour BioMed and Hualan Genetic Announced Collaboration to Develop Multiple Innovative Antibody Programs

CAMBRIDGE, Mass., ROTTERDAM, Netherlands, SUZHOU,China and XINXIANG, China, Sept. 11, 2020. Cambridge, MA, Rotterdam, NL, Suzhou Xinxiang, ...
View more
September 02, 2020

Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020

September, 2, 2020, Cambridge, MA, Rotterdam, NL, Shanghai, CN – Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, pr...
View more
August 31, 2020

Harbour BioMed Will Present Its New Platform HBICE™ (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit

August, 31, 2020, Shanghai, China – Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, today announced that it presented &nb...
View more